Compare Crispr Therapeutics AG (CRSP) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Suncor Energy Inc. — how do they compare? Crispr Therapeutics AG trades at $54.34 (market cap $5.17B), while Suncor Energy Inc. trades at $63.2 (market cap $73.34B). The key difference: Suncor Energy Inc. is far larger — about 14.2× Crispr Therapeutics AG's market cap, and Suncor Energy Inc. pays a 2.72% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SU | |
|---|---|---|
Market Cap | $5.17B | $73.34B |
Sector | Health | Energy |
52-Week High | $76.78 | $69.73 |
52-Week Low | $44.34 | $38.17 |
Enterprise Value | $3.59B | $80.01B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Suncor Energy (SU) trades at $60.1, down 2.04% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.27, beating estimates, and maintains a strong balance sheet with $3.48B in cash. Valuation ratios appear attractive with a P/E of 11.24 and EV/EBITDA of 5.42. Recent news highlights leadership changes, with Peter Zebedee set to become CEO in 2027.
Outlook is mixed: strong cash flow and analyst buy ratings (74% consensus) support upside, but near-term technical weakness and operational challenges from weather impacts pose risks. The stock offers value with solid profitability (ROE 19.25%) but faces volatility from oil price fluctuations and execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
